Albendazole and praziquantel

Phase 3Small molecule

UUniversidad Peruana Cayetano Heredia

Albendazole and praziquantel is one of 26 small molecule programs targeting Cysticercosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CysticercosisActive, not recruiting

MalariaActive, not recruiting

CysticercosisPhase 3

Active, not recruiting

MalariaPreclinical

Active, not recruiting

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

Albendazole and praziquantel

UUniversidad Peruana Cayetano Heredia

Phase 3

1 2

Biltricide

Bayer

Preclinical

1 3

Stelara

Johnson & Johnson

Preclinical

—4

Hydroxychloroquine Sulfate

Novartis

Preclinical

—5

Iron

WWatson Pharmaceuticals

Preclinical

1 6

IV LBH589

Novartis

Preclinical

1 7

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 8

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 9

RTS,S/AS01E

GSK

Preclinical

4 10

Malarone

Medicines for Malaria Venture

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Cysticercosis

NCT06376396

Q4 2028

Phase 2/3Not yet recruiting

Cysticercosis

NCT06565507

Clinical

Trials by Indication[1]

Cysticercosis3 trials

Oxfendazole in Mild Parenchymal Brain Cysticercosis

Not yet recruiting·UUniversidad Peruana Cayetano Heredia·Phase 2/3·NCT06565507·544 enrolled

Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)

Terminated·UUniversidad Peruana Cayetano Heredia·Phase 3·NCT02947581·107 enrolled

Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis

Not yet recruiting·RR-Evolution Worldwide S.r.l. Impresa Sociale·Phase 4·NCT06376396·300 enrolled

Malaria1 trial

Schistosome and Intestinal Worm Infections and Malaria Morbidity Among School and Pre-school Children in, Tanzania

Completed·DDBL -Institute for Health Research and Development·N/A·NCT00347113·620 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Albendazole and praziquantel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Albendazole and praziquantel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Albendazole and praziquantel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universidad Peruana Cayetano Heredia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversidad Peruana Cayetano Heredia

Albendazole and praziquantel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Trials by Indication[1]

Cysticercosis3 trials

Malaria1 trial

References

Drug Info

Quick Facts

Related News